FDA approves new drug to prevent joint damage in children
The US Food and Drug Administration (FDA) has approved a new use for antihemophilic factor recombinant (Kogenate FS) to reduce the frequency of bleeding episodes and prevent joint damage in children with haemophilia A.
“Administering [the drug] to children with haemophilia A on a daily basis before a bleeding event occurs will reduce bleeding into joints and help prevent joint damage, a major cause of disability in haemophiliacs,” said Jesse Goodman, MD, FDA’s Center for Biologics Evaluation and Research, Rockville, Maryland.
In a clinical trial, 65 boys aged less than 30 months with severe haemophilia A and normal joints were observed for 5 years. The patients received either 1 daily dose of the drug or 3 doses at the time of a bleeding episode.
Joint damage during a bleeding episode was 6-fold lower, and the rate of bleeding 8-fold lower, in those boys who received the drug on a daily basis compared with those who received the drug only when a bleeding episode occurred. Most patients received the drug intravenously through a catheter.
Related posts:
- What exactly is Joint custody for children and how can a father get joint custody in California?
- Prevent Food Poisoning (Kids’ Health)
- Bipolar disorder affects children as well as adults